Prelude Capital Management’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-3,935
Closed -$336K – 1336
2024
Q1
$336K Buy
3,935
+743
+23% +$58.3K 0.02% 841
2023
Q4
$273K Sell
3,192
-1,450
-31% -$125K 0.02% 778
2023
Q3
$416K Buy
+4,642
New +$414K 0.03% 534
2022
Q2
– Sell
-8,857
Closed -$560K – 1910
2022
Q1
$560K Buy
+8,857
New +$482K 0.02% 816
2021
Q4
– Sell
-13,352
Closed -$943K – 2096
2021
Q3
$943K Sell
13,352
-2,341
-15% -$148K 0.02% 598
2021
Q2
$1.05M Sell
15,693
-7,204
-31% -$510K 0.03% 590
2021
Q1
$2.54M Buy
22,897
+5,569
+32% +$689K 0.07% 266
2020
Q4
$2.06M Buy
17,328
+12,091
+231% +$1.3M 0.05% 288
2020
Q3
$457K Buy
5,237
+506
+11% +$44.2K 0.02% 459
2020
Q2
$424K Buy
+4,731
New +$478K 0.02% 512
2020
Q1
– Sell
-111
Closed -$13K – 1657
2019
Q4
$13K Buy
+111
New +$13.4K ﹤0.01% 1664
2016
Q3
– Sell
-4,362
Closed -$126K – 1677
2016
Q2
$126K Buy
+4,362
New +$132K 0.02% 666
2015
Q2
– Sell
-1,605
Closed -$72K – 1826
2015
Q1
$72K Buy
+1,605
New +$67.1K 0.01% 1151

Other funds holding HAE

Prelude Capital Management's HAE Position: Q2 2024 in Review

Prelude Capital Management sold out of Haemonetics (HAE) in Q2 2024, closing a stake of 3,935 shares — an estimated $336K sold.

Prelude Capital Management first reported a position in HAE in Q1 2015 and held it in 13 quarters. The position peaked at $2.54M in Q1 2021. 317 funds tracked by Wall St. Rank hold HAE as of Q2 2024.

  • Prelude Capital Management reported no remaining Haemonetics position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 3,935 Haemonetics shares in Q2 2024, an estimated $336K.
  • Prelude Capital Management first reported a position in Haemonetics in Q1 2015 and held it in 13 quarters.
  • Prelude Capital Management's Haemonetics position peaked at $2.54M in Q1 2021.
  • 317 funds tracked by Wall St. Rank held Haemonetics as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.